GKN2 and gastric cancer: Specifically, gastrokine-2 expression was reduced in 19 (73.07%), 32 (82.05%) and 7 (63.64%) of the 26 diffuse-, 39 intestinal- and 11 mixed-type gastric cancer samples, respectively.